(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

YOCHANRA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

YOCHANRA

ST13

US500000097402108

Class

5

Filing

97402108

Registration

7394944

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

37

Latest update

05/28/2024

Trademark type

Word

Nice classes

5

Filing date

05/09/2022

Registration date

05/28/2024

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/28/2024

Last transaction

05/28/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

Drawing code

4

Owner type

03

Owner location

Nanjing, Jiangsu, CN

Examiner

MAYES, LAURIE ANN

Law office

L10

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

TransThera Sciences (Nanjing), Inc.

Representatives

Michael T. Smith Birch Stewart Kolasch & Birch, LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; drugs for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemico-pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biological preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; bulk medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biochemical medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines in the nature of tablets for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders in the nature of capsule; injectable medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders

Publications

History of USPTO decisions and trademark events.

37 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/28/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

05/28/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

03/12/2024

PUBO

PUBLISHED FOR OPPOSITION

03/12/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/21/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

02/21/2024

OTHE

CASE RETURNED TO EXAMINATION

02/08/2024

IUCN

NOTICE OF ALLOWANCE CANCELLED

02/08/2024

JURT

JURISDICTION RESTORED TO EXAMINING ATTORNEY

02/07/2024

PCBG

PETITION TO DIRECTOR - CHANGE BASIS - GRANTED

02/07/2024

APET

ASSIGNED TO PETITION STAFF

02/06/2024

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

01/20/2024

EX1G

SOU EXTENSION 1 GRANTED

01/18/2024

EXT1

SOU EXTENSION 1 FILED

01/18/2024

EEXT

SOU TEAS EXTENSION RECEIVED

01/18/2024

TPAD

TEAS PETITION TO AMEND BASIS RECEIVED

01/10/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

11/09/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

11/09/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

11/09/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

11/09/2023

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

11/09/2023

WOAG

WITHDRAWAL OF ATTORNEY GRANTED

09/12/2023

WOAR

TEAS WITHDRAWAL OF ATTORNEY RECEIVED

09/12/2023

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

07/18/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/23/2023

PUBO

PUBLISHED FOR OPPOSITION

05/23/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/03/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/17/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/15/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/14/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/14/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

03/03/2023

GNRT

NON-FINAL ACTION E-MAILED

03/03/2023

CNRT

NON-FINAL ACTION WRITTEN

03/03/2023

DOCK

ASSIGNED TO EXAMINER

02/25/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/16/2022

NWAP

NEW APPLICATION ENTERED

05/12/2022

Continuous trademark protection

Get notified about every new filing that threatens YOCHANRA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.